Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A single fluocinolone acetonide 0.18 mg intravitreal implant delivered lasting improvements in patients with noninfectious posterior segment uveitis. The phase 4 SYNCHRONICITY study met both primary endpoints — central subfield thickness and visual acuity — at 6 months, with benefits sustained through 24 months. No new safety signals were identified.
The phase 4 SYNCHRONICITY study has good news for patients with noninfectious posterior segment uveitis (NIU-PS): a single fluocinolone acetonide 0.18 mg intravitreal implant (ANI Pharmaceuticals) delivered meaningful and durable improvements across both anatomical and functional measures. Findings were presented at Uveitis Subspecialty Day at the American Academy of Ophthalmology annual meeting in New Orleans.
The study enrolled adults with active or recurrent NIU-PS, macular edema, and a prior response to corticosteroids. Patients received one implant on day 1 and were followed for 24 months — no repeat dosing required.
Why it matters: NIU-PS is notoriously difficult to manage, and long-acting depot therapies like this implant could reduce treatment burden while maintaining disease control. The clean safety profile — consistent with known corticosteroid implant risks — adds confidence for clinicians considering this option, though IOP and cataract monitoring remain important.
